TipRanks on MSN

Eupraxia Pharmaceuticals Reports Promising 52-Week Data for EoE Treatment

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) just unveiled an update. On November 13, 2025, Eupraxia Pharmaceuticals announced additional 52-week ...

Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications ...

Discover key insights from Trevi Therapeutics' Q3 2025 earnings call, including clinical progress, strong financials, and upcoming regulatory milestones.

P3 Health Partners outlines $120M–$170M EBITDA expansion opportunity for 2026 through ...

Get key insights from P3 Health Partners’ Q3 2025 earnings call—$100M EBITDA gains, cost control, and 2026 profitability outlook.

Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts

Q3 2025 Management View CEO Steven Lo announced a major partnership with Dynavax, under which Vaxart could receive up to $700 million in license, regulatory, and milestone fees, as well as royalties ...